Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Vinca Raymonde Lardans has worked on the following 11 EPO patent applications which have been published in the last five years:

EP11715370

COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER

IPC classification:
A61K 31/436, A61K 31/519, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11791110

SALT(S) OF 7-CYCLOPENTYL-2 -(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF

IPC classification:
A61K 31/519, A61P 35/00, C07D 401/12
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12732760

COMBINATION THERAPY

IPC classification:
A61K 31/506, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
PATENT GRANTED
EP12735408

COMBINATION THERAPY COMPRISING A CDK4/6 INHIBITOR AND A PI3K INHIBITOR FOR USE IN THE TREATMENT OF CANCER

IPC classification:
A61K 31/4439, A61K 31/519, A61K 31/535, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13772621

COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE

IPC classification:
A61K 31/198, A61K 31/4985, A61K 31/505, A61K 31/519, A61P 35/00, C07D 239/94, C07D 487/04, C07D 491/04
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13802807

COMBINATION THERAPY

IPC classification:
A61K 31/436, A61K 31/519, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13812167

PHARMACEUTICAL COMBINATION COMPRISING BINIMETINIB

IPC classification:
A61K 31/4184, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14710654

ORAL FORMULATIONS OF DEFERASIROX

IPC classification:
A61K 9/20, A61K 9/28, A61K 9/50, A61K 31/4196, A61P 39/04
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis AG
Status:
EXAMINATION IN PROGRESS
EP14752433

COMBINATION THERAPY FOR THE TREATMENT OF CANCER

IPC classification:
A61K 31/519, A61K 31/551, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14824963

COMBINATION THERAPY COMPRISING AN INHIBITOR OF JAK, CDK AND PIM

IPC classification:
A61K 31/444, A61K 31/519, A61K 45/06, A61P 35/02
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP16188627

ORAL FORMULATIONS OF DEFERASIROX

IPC classification:
A61K 9/20, A61K 9/28, A61K 31/4196, A61P 39/04
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS

Please Sign in to use this feature